These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240 [TBL] [Abstract][Full Text] [Related]
11. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501 [TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602 [TBL] [Abstract][Full Text] [Related]
13. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Tham SM; Angus JA; Tudor EM; Wright CE Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704 [TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]